How do GHRH analogs work?
To compare tesamorelin and sermorelin, it helps to start with the pathway they both act on. Growth hormone–releasing hormone (GHRH) is produced by the hypothalamus and travels to the anterior pituitary, where it binds to GHRH receptors and stimulates the secretion of growth hormone (GH). GH then acts on peripheral tissues and stimulates the liver to produce insulin-like growth factor 1 (IGF-1), which mediates many of GH’s downstream effects on body composition, metabolism, and cellular repair.
Both tesamorelin and sermorelin are synthetic GHRH analogs — they bind to the same receptor as endogenous GHRH and produce the same upstream signal. Neither directly injects growth hormone into the body; instead, they prompt the pituitary to release the body’s own GH in a pattern that preserves the normal pulsatile release pattern. This is considered advantageous over direct growth hormone administration because it maintains natural feedback regulation.
How do tesamorelin and sermorelin differ structurally?
Sermorelin: the 29-amino-acid fragment
Sermorelin is a synthetic version of the first 29 amino acids of native GHRH(1-44). Researchers demonstrated that this N-terminal 29-amino-acid fragment retained full biological activity at the GHRH receptor, making it a functional and more compact analog of the full-length hormone.
Sermorelin was FDA-approved in 1997 under the brand name Geref for the diagnostic evaluation and treatment of growth hormone deficiency in children. The approval was voluntarily withdrawn by the manufacturer in 2008 for commercial reasons, not for safety or efficacy concerns. It remains available through licensed 503A compounding pharmacies with a clinician prescription — making it one of the most accessible GHRH analogs for clinician-supervised use today.
Tesamorelin: the stabilized full-length analog
Tesamorelin is a synthetic analog of the full 44-amino-acid GHRH sequence, with a chemical modification: a trans-3-hexenoic acid group attached to the N-terminus. This modification increases metabolic stability by protecting the peptide from degradation by dipeptidyl peptidase IV (DPP-IV), the same enzyme that rapidly degrades native GHRH. The result is a longer half-life and greater sustained GH stimulation compared to unmodified GHRH.
Tesamorelin (brand name Egrifta) received FDA approval in 2010 for the specific indication of reducing excess abdominal fat in HIV-positive adults with antiretroviral-associated lipodystrophy. This is a narrow, well-defined approved indication.
What does the clinical evidence show for each?
Tesamorelin’s human evidence base
Tesamorelin has been through the full Phase III clinical trial process for its approved indication. Phase III data confirmed reductions in visceral adipose tissue in HIV-positive adults with lipodystrophy, alongside increases in IGF-1 levels. This is well-controlled human evidence for a specific, narrow population.
The question of whether these findings generalize to the broader body composition and wellness optimization uses discussed in peptide communities is an important distinction. Tesamorelin has not been through large-scale Phase III trials for general body composition improvement in otherwise healthy adults. Studies in that broader context are smaller and more preliminary.
Sermorelin’s evidence base
Sermorelin’s human evidence base comes from its FDA-approved use in pediatric GHD, from diagnostic GH stimulation test literature, and from a body of smaller studies in adults examining GH axis support. The pediatric GHD approval established both efficacy and a safety profile that has informed its clinical use. In the adult wellness and optimization context, evidence is accumulating but does not yet include the scale of controlled data that supports tesamorelin for its specific approved indication.
Same receptor, different molecule: tesamorelin carries the deeper trial evidence, while sermorelin carries the easier compounding access.
Which can be prescribed today? Regulatory status and access
Regulatory status is a practical differentiator for patients and clinicians in the US:
- Sermorelin is available through licensed 503A compounding pharmacies with a clinician prescription. It is a compoundable peptide under current FDA guidance. A licensed clinician can prescribe it for off-label uses in adults, as is standard practice across many therapeutic areas.
- Tesamorelinis FDA-approved as a finished drug product (Egrifta) for HIV-associated lipodystrophy. Like any FDA-approved drug, a clinician can prescribe it off-label. However, its compounding status is subject to the FDA’s evolving policies on bulk drug substances and GHRH analogs. Patients interested in tesamorelin should discuss access and regulatory status with a clinician who is current on the compounding landscape.
This regulatory distinction is one reason sermorelin is more commonly discussed in the context of compounding-based growth hormone optimization protocols in the US today.
Tesamorelin vs sermorelin: side-by-side comparison
| Feature | Tesamorelin | Sermorelin |
|---|---|---|
| Sequence | Full GHRH(1-44) + trans-3-hexenoic acid modification | Truncated GHRH(1-29) fragment |
| FDA history | Approved 2010 (Egrifta) — HIV lipodystrophy | Approved 1997 (Geref); voluntarily withdrawn 2008 (not safety-related) |
| 503A compounding access | Restricted (approved drug rules apply) | Widely available via compounding pharmacies |
| Metabolic stability | Higher (DPP-IV-resistant modification) | Lower (faster enzymatic degradation) |
| Human evidence base | Phase 3 RCTs in HIV-lipodystrophy; smaller studies in non-HIV adults | FDA-grade pediatric GHD trials; smaller adult studies |
| Common adverse effects | Injection-site reactions, edema, arthralgia, IGF-1 elevation | Injection-site reactions, headache, flushing, IGF-1 elevation |
Safety considerations for GHRH analog therapy
Both tesamorelin and sermorelin share the general safety considerations of GHRH class compounds:
- Active malignancy: Because growth hormone can stimulate IGF-1, which has mitogenic (cell-growth-stimulating) properties, GHRH analogs are contraindicated in patients with active cancer. Clinicians evaluate personal and family cancer history as part of the pre-treatment assessment.
- Pituitary pathology: Because these compounds act on the pituitary, patients with pituitary tumors or other pituitary conditions require evaluation before use.
- Glucose metabolism: Growth hormone has anti-insulin effects. Patients with diabetes or insulin resistance require monitoring of glucose control during therapy.
- Injection site reactions: Common minor adverse effects include redness, pain, or swelling at the subcutaneous injection site.
Baseline IGF-1 measurement is standard before initiating either compound. Follow-up IGF-1 monitoring allows clinicians to confirm the GH axis is responding and levels remain within a physiologically appropriate range.
Frequently asked questions
- What is the difference between tesamorelin and sermorelin?
- Both are synthetic analogs of growth hormone–releasing hormone (GHRH) that stimulate the pituitary to release growth hormone. Sermorelin is a 29-amino-acid fragment of native GHRH(1-44). Tesamorelin is a full-length GHRH analog (44 amino acids) modified with a trans-3-hexenoic acid group for increased stability. Tesamorelin has FDA approval for HIV-associated lipodystrophy; sermorelin was FDA-approved for pediatric growth hormone deficiency (approval withdrawn for commercial reasons, not safety) and is available via compounding.
- Which is stronger: tesamorelin or sermorelin?
- Tesamorelin produces greater GH and IGF-1 elevation in clinical studies, partly due to its structural modification increasing metabolic stability. Whether "stronger" translates to better outcomes for a given individual depends on the clinical goal and their baseline GH axis function.
- Is tesamorelin FDA-approved?
- Tesamorelin (brand name Egrifta) is FDA-approved specifically for the treatment of excess abdominal fat in HIV-positive adults receiving antiretroviral therapy. It is not FDA-approved for general body composition or anti-aging purposes.
- Can sermorelin be prescribed by a clinician?
- Sermorelin is available through licensed 503A compounding pharmacies with a clinician prescription. It is a Tier 1 peptide under current FDA compounding guidance and a commonly used option in clinician-supervised growth hormone optimization protocols.
- What should I ask a clinician about GHRH analog therapy?
- Ask about baseline IGF-1 levels, which peptide or combination is appropriate for your goals, how outcomes are monitored, what the expected timeline for response is, and whether you have any contraindications (active malignancy, pituitary pathology, uncontrolled diabetes).
The takeaway: two related tools with different access profiles
Tesamorelin and sermorelin share a mechanism and a class but differ in their structural stability, their depth of human evidence for specific indications, and their current regulatory and access profile in the US compounding environment. Sermorelin’s compounding availability and established track record in clinician-supervised GH axis support protocols makes it the more commonly accessible starting point today.
Individuals interested in growth hormone optimization should work with a clinician who measures baseline and follow-up IGF-1, personalizes dosing, and can explain the current regulatory landscape accurately. Learn more about sermorelin and how it fits into clinician-supervised protocols.